Compare Smith & Nephew plc (SNN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while YieldMax Universe Fund of Option Income ETFs trades at $7.53. The key difference: Smith & Nephew plc pays a 2.85% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.
| SNN | YMAX | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $38.53 | $13.14 |
52-Week Low | $27.80 | $7.27 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
YMAX trades at $7.70 with a slight 0.13% daily gain, showing modest positive momentum. The technical outlook is bullish with moving averages supporting upward movement, though oscillators remain neutral. Recent news highlights the fund's weekly dividend distributions but also raises concerns about NAV erosion and sustainability of the high-yield strategy. The fund's structure as a fund-of-funds adds layers of costs that impact overall returns.
YMAX faces significant challenges with declining share price despite high distributions, suggesting the current yield may be unsustainable. The fund's principal erosion and structural cost issues present substantial risks for income-focused investors. While technical indicators show short-term bullish signals, fundamental concerns about the distribution policy and NAV performance warrant cautious consideration for long-term investment viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
